Sarepta Therapeutics (SRPT) Interest Expenses (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Interest Expenses of $1.0 billion for Q1 2026, up 4.56% year-over-year from $989.6 million in Q1 2025, and up 7851.28% quarter-over-quarter from $13.0 million in Q4 2025.
Sarepta Therapeutics (SRPT) Interest Expenses (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Interest Expenses rose 4.56% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 4.56% YoY), while the FY2025 annual figure was $1.1 billion, up 160.43% from the prior year.
- Interest Expenses for Q1 2026 stood at $1.0 billion, up from $13.0 million in the prior quarter.
- The five-year high for Interest Expenses was $1.1 billion in Q2 2025, with the low at -$38.8 million in Q4 2023.
- The 5-year median for Interest Expenses is $13.0 million (2025), against an average of $304.1 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses tumbled 1762.92% in 2023, then soared 23323.01% in 2025.
- Sarepta Therapeutics' Interest Expenses stood at -$2.1 million in 2022, then sank by 1762.92% to -$38.8 million in 2023, then climbed by 13.47% to -$33.6 million in 2024, then surged by 138.78% to $13.0 million in 2025, then surged by 7851.28% to $1.0 billion in 2026.
- Business Quant data shows SRPT's Interest Expenses at $1.0 billion in Q1 2026, $13.0 million in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -21.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.51 Mn |
| Jun 30, 2026 | -21.51 Mn |
| Mar 31, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 13.01 Mn |
| Dec 31, 2025 | 13.01 Mn |
| Sep 30, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.10 Bn |
| Jun 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 1.13 Bn |
| Mar 31, 2025 | 989.60 Mn |
| Mar 31, 2025 | 989.60 Mn |
| Dec 31, 2024 | -33.56 Mn |
| Dec 31, 2024 | -33.56 Mn |
| Sep 30, 2024 | 897.00 Mn |
| Sep 30, 2024 | 897.00 Mn |
| Jun 30, 2024 | 4.83 Mn |
| Jun 30, 2024 | 4.83 Mn |
| Mar 31, 2024 | 7.19 Mn |
| Mar 31, 2024 | 7.19 Mn |